

## Supplementary Material

### A HUMAN LIN- CD123+ CD127low POPULATION ENDOWED WITH ILC FEATURES AND MIGRATORY CAPABILITIES CONTRIBUTES TO IMMUNOPATHOLOGICAL HALLMARKS OF PSORIASIS

Mora-Velandia Luz<sup>1,2</sup>, Castro-Escamilla Octavio<sup>1,2</sup>, González-Méndez Andrés<sup>1</sup>, Aguilera-Flores Cristina<sup>1</sup>, Velázquez-Avila Martha<sup>4</sup>, Tussié-Luna María Isabel<sup>5,6</sup>, Jesús Martínez-Barnetche<sup>7</sup>, Juan Téllez-Sosa<sup>7</sup>, Maldonado César<sup>3</sup>, Jurado-Santacruz Fermín<sup>3</sup>, Ferat-Osorio Eduardo<sup>1</sup>, Pelayo Rosana<sup>4</sup> and Bonifaz Laura<sup>1\*</sup>.

1. Unidad de Investigación Médica en Inmunoquímica Hospital de Especialidades Centro Médico Nacional Siglo XXI. Instituto Mexicano del Seguro Social. Mexico city, Mexico.

2. Universidad Nacional Autónoma de México (UNAM). Mexico city, Mexico.

3. Centro Dermatológico “Dr. Ladislao de la Pascua”, Secretaría de Salud de la Ciudad de México. Mexico city, Mexico.

4. Unidad de Investigación en Enfermedades Oncológicas, Hospital de Oncología, Centro Médico Nacional 'Siglo XXI'. Mexico city, Mexico.

5. División de Investigación; Facultad de Medicina; Universidad Nacional Autónoma de México (UNAM). Mexico city, Mexico.


6. Unidad de Investigación en Virología y Cáncer; Hospital Infantil de México “Federico Gómez”. Mexico city, Mexico.

7. Centro de Investigación Sobre Enfermedades Infecciosas. Instituto Nacional de Salud Pública. Cuernavaca, Morelos México



Correspondence:

Laura Bonifaz


e-mail: labonifaz@yahoo.com

**A)****B)**


Lin MIX: CD3, CD14, CD19, CD94, HLA-DR

**C)**Lin MIX: CD3, CD14, CD19, CD94, HLA-DR + Fc $\epsilon$ R


**Supplementary Figure 1:** In A) Gate analysis on the Lin- CD123+ and pDCs, and compared expression of HLA-DR and BDCA-2 in both populations B) and C): Identification of Lin- CD123+ and Lin- CD127+ cells using -/+ anti-Fc $\epsilon$ R in the lineage cocktail respectively.




**Supplementary Figure 2:** Supplementary figure X: DH1-6-JH incomplete rearrangement analysis. Genomic DNA from each subpopulation was subjected to multiplexed PCR amplification using the BIOMED-2 primers set for DH1-6-JH incomplete rearrangements (Tube D) according to (Ref 40). PCR products were resolved in a Agilent 2100 Bioanalyzer capillary electrophoresis system with an 1000 DNA chip. Product size in base pairs in the x-axis (cropped for clarity) and relative amount (fluorescence units, y-axis). A) Oral swab from a healthy donor as a negative control; B) Sorted CD19<sup>+</sup> B cells from a healthy donor; C) Sorted CD123<sup>+</sup> CD127<sup>low</sup> from a healthy donor; D) CD127<sup>+</sup> classical ILC from a healthy donor; and E) Acute B-cell leukemia cell line NAL-M6. The expected range of DH1-6-JH rearrangements is 110-420 bp (red bar). A germline ~340 bp product (\*) is consistently amplified and serves as an internal positive control. Low weight electrophoretic front (\*\*).




**Supplementary Figure 3:** DH7-JH incomplete rearrangement analysis. Genomic DNA from each subpopulation was subjected to PCR amplification using the BIOMED-2 DH7-JH primer pair for incomplete rearrangements (Tube E) according to (Ref1). PCR products were resolved in a Agilent Bioanalyzer capillary electrophoresis system with an 1000 DNA chip. Product size in base pairs in the x-axis (cropped for clarity) and relative amount (fluorescence units, y-axis). A) Oral swab from a healthy donor as a negative control; B) Sorted CD19<sup>+</sup> B cells from a healthy donor; C) Sorted CD123<sup>+</sup> CD127<sup>low</sup> from a healthy donor; D) CD127<sup>+</sup> classical ILC from a healthy donor; and E) Acute B- cell leukemia cell line NAL-M6. The expected range of DH7-JH rearrangements is 100-130 bp (red bar). Two germline ~211 and 419 bp products (\*) are consistently amplified and serve as internal positive controls. Low weight electrophoretic front (\*).

**A)****B)**


CD127

**C)**

**Supplementary Figure 4:** In **A)** Percentages of Lin<sup>-</sup> CD123<sup>+</sup> and Lin<sup>-</sup> CD127<sup>+</sup> sorted cells. Gated on Lin<sup>-</sup> cells. **B)** CD127 expression in Lin<sup>-</sup> CD123<sup>+</sup> after 3.5 hrs of transmigration assay in response SDF-1(red histogram) or RPMI (blue histogram). MF values representative of three experiments are shown. **C)** Graph of CD127 MF from three independent experiments. Control: n = 6 and SDF-1: n= 11



**Supplementary Figure 5:** A) IL-4 and IL-13 expression in Lin<sup>-</sup> CD123<sup>+</sup> and Lin<sup>-</sup> CD127<sup>+</sup> within PBMCs cultured +/- ILC2 activation cocktail for 18 hrs. and B): IL-17 and IL-22 expression in Lin<sup>-</sup> CD123<sup>+</sup> and Lin<sup>-</sup> CD127<sup>+</sup> within PBMCs cultured +/- ILC3 activation cocktail for 18 hrs. Density plots are representative of at least three independent experiments



## Supplementary Figure 6:

ROR $\gamma$ t expression in total skin cells in A) Lin<sup>-</sup> CD123<sup>+</sup> and B) Lin<sup>-</sup> CD127<sup>+</sup> cell populations . Left: FMO controls, Right: ROR $\gamma$ t staining